Doxorubicin does not spread systemically following a local injection into the eyelids of rabbits

Current Eye Research

Volumn 19, Issue 3, 1999, Pages 285-289

  McLoon, Linda Kirschen ^a   Josephson, Kristopher ^a   Wirtschafter, Jonathan ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Doxorubicin; Eyelid; High performance liquid chromatography (HPLC); Orbicularis oculi muscle; Rabbit

Indexed keywords

DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEPHAROSPASM; BLOOD; CONJUNCTIVA; CONNECTIVE TISSUE; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; DRUG URINE LEVEL; EXTRAOCULAR MUSCLE; EYELID; FACE MUSCLE; HEART; HEMIFACIAL SPASM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LIVER; NONHUMAN; ORBICULARIS OCULI MUSCLE; PRIORITY JOURNAL; RABBIT; SKIN; SPLEEN; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; URINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONJUNCTIVA; CONNECTIVE TISSUE; DOXORUBICIN; EYELIDS; FACIAL MUSCLES; INJECTIONS, SUBCUTANEOUS; KIDNEY; LIVER; MYOCARDIUM; RABBITS; SKIN; SPLEEN; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0032758038     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.19.3.285.5311     Document Type: Article

References (27)

1. Wirtschafter JD. Clinical doxorubicin chemomyectomy: an experimental treatment for muscle spasms. Ophthalmology. 1991;98:357-366.
2. Wirtschafter JD. Chemomyectomy of the orbicularis oculi muscles for the treatment of localized hemifacial spasm. J Neuro-ophthal. 1994;14:199-204.
3. McLoon LK, Bauer G, Wirtschafter JD. Quantification of muscle loss in the doxorubicin treated orbicularis oculi muscle of the monkey. Invest Ophthal Vis Sci. 1991;32: 1667-1673.
4. McLoon LK, Luo XX, Wirtschafter JD. Acute morphologic changes in orbicularis oculi muscle after doxorubicin injection into rabbit eyelid. Muscle Nerve. 1993; 16:737-743.
5. McLoon LK, Wirtschafter JD, Cameron JD. Muscle loss from doxorubicin injections into the eyelids of a patient with blepharospasm. Amer J Ophthal 1993;116:646-648.
6. Arcamone F. Doxorubicin, Anticancer Antibiotics: Medicinal Chemistry, New York, Academic Press, 1991:Vol. 17.
7. Lefrak EA, Pitha J, Rosenheim S, Gottlieb A. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer. 1973;32:302-314.
8. Lenaz L, Page J. Cardiotoxicity of Adriamycin and related anthracyclines. Cancer Treat Rev. 1976;3:111-120.
9. Mazue G, Iatropoulos M, Imondi A, Castellino S, Brughera M, Podesta A, Della Tone P, Moneta D. Anthracyclines: a review of general and special toxicity studies. Int J Oncol. 1995;7:713-726.
10. Speth PAJ, van Hoesel QGCM, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokin. 1988; 15:15-31.
11. Underferth DV, Magorien RD, Unverferth BP, Talley RL, Balzerzak SP, Baba N. Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration. Cancer Treat Rep. 1981;65:1093-1097.
12. Rudolph R, Stein RS, Patillo RA. Skin ulcers due to Adriamycin. Cancer. 1976;38:1087-1094.
13. Bowers DG, Lynch JB. Adriamycin extravasation. Plast Recontr Surg. 1978;61:686-692.
14. Jones AP, Crawford SM. Anthracycline induced toxicity affecting palmar and plantar skin. Brit J Cancer. 1989;59:814.
15. McLoon LK, Wirtschafter JD. Doxorubicin chemomyectomy: injection of monkey orbicularis oculi results in selective muscle injury. Invest Ophthal Vis Sci. 1988;29:1854-1859.
16. Rose LM, Tillery KF, El Dareer SM, Hill DL. High-performance liquid chromatographic determination of doxorubicin and its metabolites in plasma and tissue. J Chromat. 1988;425:419-423.
17. Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE. Distant effects of local injection of botulinum toxin. Muscle & Nerve. 10, 522-555.
18. Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology. 1993;43:1715-1718.
19. Dorr RT, Alberts DS, Chen HSG. Experimental model of doxorubicin extravasation in the mouse. J Pharmacol Meth. 1980;4:321-334.
20. Sonneveld P, Wassenaar HA, Nooter K. Long persistence of doxorubicin in human skin after extravasation. Cancer Treatment Rep. 1984;68:895-896.
21. Wirtschafter JD, McLoon LK. Long-term efficacy of local doxorubicin chemomyectomy in blepharospasm and hemifacial spasm patients. Ophthalmology. 1998;105: 342-346.
22. McLoon LK, Kirsch J, Cameron S, Wirtschafter JD. Injection of doxorubicin into rabbit eyelid does not result in loss of facial motor neurons. Brain Res. 1994;641: 105-110.
23. Preiss R, Sohr R, Kittelmann B, Muller E, Haase D. Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites. Int J Clin Pharmacol Therap Toxicol. 1989;27:156-164.
24. Jacquet JM, Bressolle F, Galtier M, Bourrier M, Donadio D, Joudan J, Rossi JF. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol. 1990;27:219-225.
25. 2 mice. Cancer Chemother Pharmacol. 1979;2:11-14.
26. Cusack BJ, Young SP, Driskell J, Olson RD. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol. 1993;32:53-58.
27. Takanashi S, Bachur NR. Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Disp. 1976;4:79-87.